Erasca, Inc.
Overview
Erasca is a clinical-stage precision oncology company focused on shutting down the RAS/MAPK pathway, which is commonly mutated in cancer, to improve treatment outcomes for patients suffering from various cancers.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Erasca, Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Related companies
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.